A new fluid biomarker for Parkinson’s disease (PD) was developed, offering a high-accuracy biological classification, ...

In October 2024, Blackwell filed suit against Alpha News and reporter Liz Collin, who questioned the honesty of Blackwell’s expert witness testimony during the 2021 trial over the murder of Floyd.

The start of 2025 brought a familiar refrain, with Cloud Imperium CEO Chris Roberts sallying forth to declare that 'we are closer than ever to realizing a dream many have said is impossible' with ...

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in ...

Quasar Alpha, a highly advanced AI model currently undergoing pre-release testing on OpenRouter, is pushing the boundaries of what artificial intelligence can achieve in coding, animation ...

The artificial intelligence (AI) landscape is witnessing a quiet yet profound evolution with the emergence of two advanced models: Night Whisper and Quasar Alpha. These stealth releases have ...

Sheikh Tahnoon bin Zayed's Alpha Wave Global plans to acquire a 6% stake in Haldiram Snacks Food for approximately $600 million. This potential investment, following Temasek's recent acquisition of ...

About UNLOXCYT TM (cosibelimab-ipdl) UNLOXCYT is a human immunoglobulin G1 monoclonal antibody that binds PD-L1 and blocks the interaction between PD-L1 and its T cell receptors, PD-1 and B7.1 ...

The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 and PD1, key targets implicated in immune evasion by tumor cells.

UNLOXCYT is the first and only programmed death ligand-1 (“PD-L1”) blocking antibody to receive FDA marketing approval for this indication. In September 2024, Checkpoint presented longer-term ...